Simeon Schnapper, a managing partner at JLS Fund, took 30 minutes from his busy schedule to share his insights into what makes a winner in the psychedelics space.
“I don’t think a lot of people fully understand what psychedelics are, I know there’s companies going public right now, there’s great investment opportunity, but also great opportunity to bend the arc of history,” said Schnapper, in his presentation at the Benzinga Global Small Cap Conference on Thursday.
JLS Fund, an investment firm that sits at the intersection of psychedelics and technology, holds shares in companies such as MindMed MNMD, Atai Life Sciences and Wesana Health WESA, which went public earlier this week.
New Trends In Psychedelics: Schnapper sees a few trends picking up in the sector. One involves M&A, as smaller companies are acquired by larger public or soon-to-be-public, companies. Another trend is the integration of digital therapeutics into business models.
Electronic devices that can amplify or emulate psychedelic experiences are also something to look at, Schnapper said.
“From the virtual reality side, we’re tracking 38 plays that integrate with some modality of psychedelic psychotherapy. On the wearables side, that’s in the thousands.”
But in order to choose investments, Schnapper said JLS Fund looks at grey markets as a window into the future.
“Decriminalization is one of those signals that we look at. We say, ‘well what’s happening on this side, how is it formulating between the black market and the regulated market?’ That really moves the needle.”
In the past year and a half, a number of jurisdictions within the U.S. approved decriminalization measures for naturally occurring psychedelics, including Oakland, Denver, Ann Arbour and three suburbs of Detroit. Oregon was the first state to remove penalties on the use of all drugs, and launched a program for licensed psilocybin therapy in late 2020.
Patents In The Psychedelics Space: Schnapper referred to the issue of intellectual property, a topic that has become a bone of contention in the sector in recent months.
The investor finds it useful to divide the space in two, in order to address the patents issue.
In one category, Schnapper places classical psychedelics like LSD and psilocybin as these don’t have IP protection since they’re either natural molecules or synthetic compounds discovered decades ago, with expired patents.
“Currently the mindset is ‘we have to have IP to get investors in’,” Schnapper explained, though he doesn’t fully agree.
In order to get IP for classical psychedelics, companies develop protocols around the therapeutic application of a particular molecule.
This is used to create “either competitive edge, a mote, some might even conjecture a monopoly.”
On the other hand, there are novel molecules, which are newly discovered compounds created by biotech companies working in research today.
These involve “developing entirely new compound entities,” that can offer greater safety, improved dosing or better shelf life.
“That’s the debate, and the jury is currently out...not just figuratively,” Schnapper said.
“As you come into any nascent industry with IP, you get into litigation. Right now it’s contentious, nothing’s public, but it’s something investors should look at very heavily.”
Schnapper recommends that investors review which companies have made patent claims and which actors in the space could litigate against those claims.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.